Objective To assess rotavirus vaccine and pneumococcal conjugate vaccines (PCVs) cumulative impact on the pediatric emergency department visits and hospitalization rates in children <2 years of age in southern Israel between April 2006 and March 2014. Study design This prospective, population-based observational study calculated the rates of rotavirus gastroenteritis (RVGE), non-RVGE, community-acquired alveolar pneumonia (CAAP), nonalveolar lower respiratory tract infection, and all-cause hospital visits. PCV7, PCV13, and rotavirus vaccination programs were implemented in Israel in July 2009, November 2010, and January 2011, respectively.
Moreover, 1 study suggested that diarrhea may increase the risk of subsequent pneumonia in young children, 14 pointing to potential synergistic benefits of RVVs and PCVs.
In Israel, PCVs and RVVs were introduced to the National Immunization Plan (NIP) within a 1.5-year interval, enabling observation of their cocontribution to reduction in burden of diseases. Indeed, a substantial reduction of both RVGE and alveolar pneumonia was observed in young children in southern Israel after rapid uptake of PCV and RVV. 5, 6 Our current aim was to assess cocontribution introduction of RVV and PCV on reduction of hospital burden caused by diarrhea and LRI in children <2 years of age in southern Israel. Specifically, we examined the following 
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community-acquired entities: RVGE, gastroenteritis not caused by rotavirus (non-RVGE), alveolar pneumonia, and nonalveolar LRI. We studied the associated reduction in burden on rates of both outpatient pediatric emergency department visits and hospitalizations.
Methods
This prospective, population-based observational study was conducted over an 8-year period (April 2006 to March 2014). The study was approved by the Institutional Ethics Committees of the Soroka University Medical Center (SUMC). The SUMC is the only hospital in the Negev district of southern Israel, providing primary and referral health services to the entire population of the region (>640 000 inhabitants and approximately 30 000 children under 2 years of age in 2012). 5, 6, 15 More than 95% of the children living in the region are served by the SUMC, enabling incidence rate calculations. Similarly, even though patients from other regions are treated in our hospital, this is the case in <5% of all pediatric ED and hospitalization cases.
Two distinct ethnic populations reside side by side in southern Israel: The Bedouin Muslim population, similar to a developing population, and the Jewish population, whose lifestyle is similar to that of a developed population. 5, 6 The socioeconomic conditions and lifestyles of the 2 populations differ and social contacts between them, especially between children, are uncommon. However, both have access to the same medical services (both clinic and hospitalization services). The proportion of children of each ethnic group born at the SUMC during the study period was similar; approximately 7500 Jewish children and approximately 7200 Bedouin children. 6, 15 Hospitalization rates for respiratory infections and gastroenteritis were reported previously to be higher among the Bedouin population. 5, 6 PCV and RVV Introduction to the Israeli NIP and Uptake The 7-and 13-valent PCVs (PCV7 and PCV13) and RVV were introduced into the Israeli NIP in July 2009, November 2010, and January 2011, respectively.
The PCV7 was licensed in Israel in mid 2007, and was used sporadically until 2009. In July 2009, the PCV7 was introduced to the NIP (administered at 2, 4, and 12 months of age) with a catch-up campaign in children <2 years of age. In November 2010, PCV13 gradually replaced PCV7, without a further catch-up program. 16 It was estimated that in 2007-2008, the proportion of 12-to 23-month-old Jewish and Bedouin children with ≥2 PCV doses was approximately 25% and <5%, respectively. 16 In June 2010, 2011, 2012, and 2013, the proportion of 7-to 11-month-old children who had received ≥2 doses of any PCV was 81%, 90%, 89%, and 89%, respectively. The respective figures for PCV13 were 3%, 30%, 86%, and 89%. 6 These rates were similar in the Jewish and Bedouin populations.
Two RVVs (a monovalent vaccine, Rotarix, and a pentavalent vaccine, Rotateq) were licensed in Israel in 2007 but initially were used scarcely. From mid-2008 to December 2010, they were distributed at reduced costs by the health maintenance organizations, covering approximately 25% of the Jewish children with ≥1 doses. In contrast, the Bedouin population did not use any RVV during that period. 5 In January 2011, the pentavalent RVV was introduced into the Israeli NIP, and offered free of charge to all infants born after September 1, 2010; it was administered at 2, 4, and 6 months of age. 5 RVV uptake was rapid and by the end of 2012, approximately 95% and approximately 85% of the Jewish children 7-11 months of age received ≥2 and full 3 doses, respectively. The respective rates among Bedouin infants were approximately 90% and approximately 65%.
5 Alveolar Pneumonia. A child was diagnosed radiologically as having alveolar pneumonia according to the World Health Organization's "Standardization of Interpretation of Chest Radiographs" working group, as described previously. 6 Briefly, alveolar pneumonia was defined as a dense opacity that may be a fluffy consolidation of a portion, whole of a lobe, or the entire lung, often containing air bronchogram(s) and sometimes associated with pleural effusion. All chest radiographs were collected daily and were evaluated separately by 2 pediatric infectious disease specialists who read all the chest radiographs independently. Further analysis was performed by an independent pediatric radiologist who was unaware of the clinical data and the pediatricians' analysis. The presence of radiologically diagnosed alveolar pneumonia was confirmed by agreement between ≥1 of the study pediatric infectious disease specialists and the study pediatric radiologist.
LRI (Other Than Alveolar Pneumonia)
. LRI was diagnosed clinically by the treating physician. Diagnoses compatible with LRI (eg, bronchiolitis, respiratory distress, hypoxemia, pneumonia) were made by International Classification of Diseases, 9th edition codes, and radiologically confirmed alveolar pneumonia was excluded from these cases. For pediatric ED visits and hospitalized cases, a study member went over all medical charts and determined (coded) the diagnosis. If the coding for the pediatric ED patient did not include LRI, but the study coordinator coded it as LRI, it was counted as LRI. For double coding (both ER and hospitalized patient), cases were only counted once, as hospitalized LRI.
RVGE.
Episodes were defined as acute diarrhea lasting <7 days before enrollment, with a positive stool enzyme immunoassay for rotavirus antigen, as previously described. 5 Briefly, study staff located at the pediatric ED identified all eligible children daily, year round. All children <5 years with a history of diarrhea/vomiting (≥3 watery or looser-than-normal stool within a 24-hour period and/or forceful vomiting) were offered participation in the study upon presentation to the pediatric ED. A stool sample was collected from the diaper or directly from the child within 48 hours of admission. All samples were tested by enzyme immunoassay for rotavirus. Non-RVGE. Episode was defined as a diarrheal disease lasting from <7 days before enrollment with a negative stool enzyme THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 182 immunoassay for rotavirus. For both RVGE and non-RVGE, episodes were separated by >28 days from a previous diarrheal episode. Extrapolation for children enrolled in the study, but who failed to provide samples (both those with diarrheal episodes who were not approached and cases with no parental consent) was conducted separately for each ethnic group and each age group, by calendar year and month, and separately for children who were hospitalized and for outpatient pediatric ED visits, as described. 5 We conducted these extrapolations using the assumption that the missing samples had the same proportion of rota-negative and rota-positive samples as the tested samples. For missed samples (refusals or episodes outside the study hours), diagnoses compatible with GE (eg, diarrhea, gastroenteritis) were made by International Classification of Diseases, 9th edition codes, similar to the coding of LRI.
Statistical Analyses. Only children residing in the Negev region were included in the study.
The incidence of all pediatric ED visits for RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI were calculated for the period between April 2006 and March 2014. Rates per 1000 population <2 years of age were calculated annually (April through March, each year) as the number of cases divided by the total population at risk during each year of the study.
Because the H1N1 influenza outbreak occurred in the year between April 2009 and March 2010, incidence rate ratios and 95% CI of RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI were calculated comparing rates in the 3 years between April 2006 and March 2009 (pre-vaccines period) with the last study year, namely, April 2013 through March 2014 (when both vaccine uptakes were approximately 90%).
Additionally, proportions (percentage) and ORs, with 95% CIs were calculated for RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI out of all-cause pediatric ED visits in the peak respiratory and diarrhea season (October through March). The mean annual duration of hospitalization was calculated for RVGE, non-RVGE, and alveolar pneumonia, but not for nonalveolar LRI (missing data).
Results
Throughout the study, 3092, 10 591, 4383, 19 525, and 116 321 episodes in children <24 months of age of communityacquired RVGE, non-RVGE, alveolar pneumonia, nonalveolar LRI, and all-cause hospital visits were recorded, respectively. Of the overall 37 591 children with ≥1 of the diagnoses listed, 19 466 (51.8%) and 18 125 (48.2%) were in children who were hospitalized and children who visited the pediatric ED as outpatients, respectively.
Dynamics of RVGE, Non-RVGE, Alveolar
Pneumonia, and Nonalveolar LRI Rates Throughout the study, RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI rates (per 1000 children <2 years of age) all were reduced significantly by 78%, 21%, 46%, and 7%, respectively, in children who were hospitalized ( Table I and  Table I . Annual rates per 1000 children <2 years of age and incidence rate ratios of RVGE, non-RVGE, alveolar pneumonia, and nonalveolar lower respiratory hos- 
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ORIGINAL ARTICLES Figure 1 ). This could be translated to overall reductions of 7.2, 4.0, 7.1, and 3.2 episodes per 1000 population <2 years of age in hospitalizations owing to RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI, respectively. The respective decreased in outpatient pediatric ED visits were 80%, 16%, 67%, and 13%. This could be translated to overall reductions of 6.8, 4.6, 4.9, and 4.5 episodes per 1000 population <2 years of age of outpatient pediatric ED visits owing to RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI, respectively. These decreases resulted in overall respective reductions in hospital visits by 79%, 18%, 53%, and 10% (all P < .05).
Although RVGE and alveolar pneumonia rates decreased constantly in each year after the introduction of RVV and PCVs, the rates of non-RVGE and nonalveolar LRI showed fluctuations. This was most apparent in 2009-2010 and 2010-2011, when nonalveolar LRI rates peaked during the H1N1 outbreak.
Dynamics of Overall (All-Cause) Hospitalization and Outpatients Pediatric ED Visit Rates
Overall, rates of hospitalization and outpatient pediatric ED visits were reduced significantly by 11% and 12%, respectively, throughout the study (Table I and Figure 2; Figure 2 available at www.jpeds.com).
This could be translated into overall reductions of 19.0 and 40.3 episodes per 1000 population <2 years of age for hospitalization and outpatient pediatric ED visits, respectively (a total of 59.3 hospital visits per 1000 population <2 years of age). These overall reductions were derived mainly from 23% and 26% reductions in the 4 clinical entities (RVGE, non-RVGE, alveolar pneumonia, and nonalveolar LRI grouped) in hospitalization and outpatient pediatric ED visits, respectively (Table I and Figure 2) In contrast, hospitalizations rates owing to other diseases (nonrespiratory, nondiarrhea) were not reduced. Additionally, although outpatient visit rates owing to other diseases were slightly but significantly reduced by 6% when the 2013-2014 was compared with the 3 prevaccination years, the rates and dynamics of this group exhibited considerable fluctuations throughout the study.
Mean Annual Hospitalization Duration (Days) of RVGE, Non-RVGE, and Alveolar Pneumonia
The hospitalization duration (days) for non-RVGE and alveolar pneumonia decreased significantly by 23.9% (from 4.6 to 3.5) and 36.4% (from 4.4 to 2.8), respectively, and nonsignificantly by 10.8% (from 3.7 to 2.3) for RVGE, comparing the prevaccines period with the last study year (Table II) The rates of all other diagnoses increased significantly by 7.2% in children who were hospitalized, and decreased significantly by 13.6% for outpatients pediatric ED visits, when 2013-2014 was compared with 2006-2009. However, considerable fluctuations in these rates were observed throughout the study, unlike the 4 study endpoints (Table III) . Furthermore, the most remarkable reductions in pediatric ED visits for the other diagnoses occurred in the years before the introduction of PCVs and RVV.
The proportions of RVGE and community-acquired alveolar pneumonia (grouped) of all-cause hospitalizations during the peak season decreased from 19.9% to 12.3%, when the 
Discussion
In the current study, the successive introduction, within 1.5 years, of RVV and PCV to the Israeli NIP, resulted in rapid and considerable reductions in diarrhea and LRI in children <2 years of age, treated at the SUMC. Furthermore, both vaccines cocontributed to a significant reduction in overall hospital burden in the pediatric population. The decreases observed in gastrointestinal and lower respiratory tract diseases varied. Although RVGE rates declined by approximately 80% for both inpatients and outpatient pediatric ED visits, the respective decrease in alveolar pneumonia rates were by 46% and 67%. For non-RVGE and nonalveolar LRI, the rates of overall hospital burden were reduced by approximately 20% and 10%, respectively.
As expected, the most dramatic decrease was observed in RVGE. Rotavirus is the most common cause of diarrhea in young children 5 and RVGE is a well-defined disease, caused by a single pathogen. RVGE is detected early in the course of disease and is preventable by RVV, as demonstrated in this study and in many others studies worldwide evaluating its efficacy.
11
For alveolar pneumonia, the expectations were somewhat less obvious, because the etiology of pneumonia is difficult to determine. 13, 17 Nevertheless, in this regard, the impressive impact of PCV7/PCV13 on alveolar pneumonia serves as a "vaccine probe," suggesting that a major portion of alveolar pneumonia episodes are bacterial, and are caused by pneumococcal serotypes included in PCV13. This was especially pronounced for outpatient pediatric ED visits for alveolar pneumonia, where 67% reduction was observed.
Non-RVGE and nonalveolar LRI are less well-defined in terms of the causative pathogens, but some proportion is caused directly or indirectly by the pathogens covered by the 2 vaccines. Specifically, nonalveolar LRI episodes were expected to be reduced, especially in inpatients, because, among others, S pneumoniae is a "collaborator" with viruses. 17 However, the decrease is not as marked as is evident in episodes of alveolar pneumonia. The roles of vaccines in the reduction observed in non-RVGE is an intriguing question. Several speculations can be made. First, the test may have missed true RVGE episodes owing to imperfect sensitivity. However, the test used in the current study has been shown to have high sensitivity in most cases, and can detect small amounts of rotavirus. 5 Second, RVVs may reduce non-RVGE by reducing RVGE sequelae, often manifesting as secondary diarrhea, which could account for some proportion of cases.
Considerable fluctuation was noted for all other diagnoses (nonrespiratory, nondiarrheal). Specifically, for inpatients, no decreases were observed. For outpatients, although a reduction in other diagnoses rates were observed, these were documented even before vaccines were introduced and fluctuated subsequently, with no further decrease observed. This emphasizes the importance of observing multiyear dynamics from both before and after the introduction of vaccines.
The impact of RVV and PCV may not be limited to prevention of diarrhea and respiratory disease, respectively. In 1 study, it was suggested that diarrhea may increase the risk of subsequent pneumonia in young children, 14 pointing to potential synergistic benefits of RVV and PCV.
Vaccine impact was not limited to decreases in hospital visits, but also led to a reduced mean hospitalization duration of alveolar pneumonia and non-RVGE. This was especially pronounced in alveolar pneumonia, increasing vaccines impact in terms of overall reduction in hospital burden. These reductions may be attributed, at least in part, to the prevention of nosocomial infections caused by S pneumoniae and rotavirus. Indeed, in the prevaccines era, it was estimated that a substantial portion of all rotavirus hospitalizations was due to infection acquired in the hospital. 10 The impact observed in the current study on diarrhea and respiratory infections is similar to that found in other reports from different countries introducing RVV 11 or PCV. 9 Those reports focused on the impact of a single vaccine. In the US, rates of all-cause acute gastroenteritis hospitalization among children younger than 5 years of age declined by 31%-55% in the postvaccine years, 8 and a 15%-20% decline of severe (associated with hospitalization) all-cause diarrhea cases was observed in developing countries, similar to figures reported from Malawi and South Africa. 11 Similarly, a 43% decrease in rates of pneumonia hospitalization was observed in US children <2 years of age after PCV7 implementation. 9 Our study was possible because PCV and RVV were introduced to the NIP in Israel within a 1.5-year interval, enabling observation of their cocontribution to the reduction in the burden of diseases. This resulted in a reduction in all-cause hospital visits at a magnitude of approximately 12%. Because both diarrhea and respiratory diseases are seasonal, the observed reduction in allcause hospital visits was especially notable in the winter season, with approximately a 15% reduction observed. These benefits have substantial impact, in terms of public health, financial costs, and relieving the burden of hospital visits during the most cumbersome seasons.
Despite the impressive reduction seen after PCVs and RVV implementation to date, future prevention measures may allow further reduction in hospital burden. In Israel, as in many other countries, influenza vaccination coverage is relatively poor (Israeli health ministry data). Efforts have been made to increase vaccination rates by vaccinating children attending primary schools, starting in the 2016-2017 school year (http://www.health.gov.il/English/News_and_Events/ Spokespersons_Messages/Pages/15042015_1.aspx). In the UK, a school vaccination program resulted in decreases in respiratory disease burden in all ages. 18 In addition, it is hoped that in the next decade, one or more vaccines against the respiratory syncytial virus will be licensed and implemented. Because the respiratory syncytial virus is the most common pathogen responsible for hospitalization owing to LRIs in young children, respiratory syncytial virus vaccines may further decrease burden of LRI.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 182
Theoretically, the reductions observed in the 4 clinical diarrhea and respiratory diseases rates could be unrelated to the introduction of these vaccines. However, the fact that hospitalization rates for other diseases increased throughout the study, as well as the observed fluctuations of those entities in pediatric ED outpatient visits rates, suggests that reductions in the 4 clinical entities evaluated were in fact driven by the introduction of both RVV and PCV. ■ 
